Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,114,297 shares of the medical research company’s stock after buying an additional 5,725 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.29% of Thermo Fisher Scientific worth $194,411,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Sharkey Howes & Javer raised its position in shares of Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the period. Beacon Trust Co. raised its position in shares of Thermo Fisher Scientific by 0.6% during the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after purchasing an additional 12 shares during the period. Dumont & Blake Investment Advisors LLC raised its position in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after purchasing an additional 15 shares during the period. Reinhart Partners Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% during the second quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock worth $598,000 after purchasing an additional 20 shares during the period. Finally, Azimuth Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 0.8% during the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock worth $493,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at 189.20 on Friday. The firm has a market cap of $73.81 billion, a price-to-earnings ratio of 32.96 and a beta of 1.05. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $194.30. The company has a 50-day moving average price of $181.07 and a 200-day moving average price of $171.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.03 earnings per share. Analysts forecast that Thermo Fisher Scientific Inc will post $9.34 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) Holdings Boosted by Sumitomo Mitsui Trust Holdings Inc.” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-holdings-boosted-by-sumitomo-mitsui-trust-holdings-inc/1600174.html.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $176.02, for a total value of $5,280,600.00. Following the transaction, the senior vice president now owns 67,016 shares in the company, valued at $11,796,156.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jim P. Manzi sold 1,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total value of $175,200.00. Following the completion of the transaction, the director now owns 38,757 shares in the company, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,738 shares of company stock worth $9,302,112. Corporate insiders own 0.49% of the company’s stock.

A number of equities research analysts have recently commented on the company. Deutsche Bank AG set a $200.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Saturday, June 10th. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Jefferies Group LLC reaffirmed a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday. Wells Fargo & Company reaffirmed an “outperform” rating and set a $200.00 price target (up previously from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $202.21.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.